CBP將英國專利藥品的232條款關稅降至零
CBP 英文原標題： GUIDANCE: Reduction of Tariffs on Patented Pharmaceuticals and Pharmaceutical Ingredients for Products of the United Kingdom Implemented by Presidential Proclamation 11020
CBP 宣布了什麼？
CBP宣布，來自英國、按HTSUS 9903.04.63申報的專利藥品及相關成分，其附加關稅由10%降至0%。此變更適用於2026年7月31日美東時間凌晨12:01（含）之後報關進口消費或從倉庫提取消費的貨物。CBP表示已更新ACE系統以反映新稅率，並提示申報人參閱先前訊息中相關的第99章分類。
Allied 的立場是什麼？
當時，這意味著Allied在2026年7月31日（含）之後為按9903.04.63申報的英國專利藥品所辦理的報關，不再適用10%的附加232條款關稅，而是0%。根據我們追蹤的資訊，目前沒有顯示此稅率之後有變動，但屬於此類別的客戶如有相關報關案件，應要求我們確認所適用的正確稅率。客戶不需自行採取行動；如對特定報關案件有疑問，請與我們聯繫。
一般資訊，並非法律意見。
CBP 訊息的英文原文說了什麼？
This message provides guidance regarding the reduction of tariffs on patented pharmaceuticals and associated pharmaceutical ingredients that are products of the United Kingdom amending Presidential Proclamation 11020, “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States.”
BACKGROUND
On July 31, 2026, the Secretary of Commerce published “Notice of Reduction of Tariffs on Patented Pharmaceuticals and Pharmaceutical Ingredients for Products of the United Kingdom Implemented by Presidential Proclamation 11020 (https://www.federalregister.gov/public-inspection/2026-15799/reduction-of-tariffs-patented-pharmaceuticals-and-pharmaceutical-ingredients-for-products-of-the)” reducing the tariff rate for patented pharmaceuticals and associated pharmaceutical ingredients that are products of the United Kingdom from 10 percent to 0 percent, effective July 31, 2026.
CBP has completed the necessary updates in the Automated Commercial Environment (ACE).
GUIDANCE
This guidance instructs importers, brokers, and filers on submitting entries to U.S. Customs and Border Protection (CBP) on patented pharmaceuticals and associated ingredients imported from the United Kingdom under Harmonized Tariff Schedule of the United States (HTSUS) heading 9903.04.63.
Effective with respect to goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. Eastern Time on July 31, 2026:
9903.04.63: Applies to patented pharmaceutical articles that are the product of the United Kingdom, as defined in U.S. note 40(c) and (g) to subchapter III.
0% additional ad valorem duty rate.
Refer to CSMS # 69395344 (https://content.govdelivery.com/bulletins/gd/USDHSCBP-422e390?wgt_ref=USDHSCBP_WIDGET_2) for Chapter 1–97 HTSUS classifications which correspond to heading 9903.04.63, and the other Chapter 99 headings established by Proclamation 11020.
For questions regarding Section 232 entry filing, contact the Trade Remedy Branch at TradeRemedy@cbp.dhs.gov (mailto:TradeRemedy@cbp.dhs.gov).
If you encounter any errors in filing an entry summary, contact your CBP client representative or the ACE Help Desk.
此訊息使用了哪些術語？
每週以電子郵件接收 CBP 訊息
每週一封英文電子郵件，列出新的 CSMS 訊息，並附淺白摘要及我們的立場。您可以隨時取消訂閱。